Kyle Piskel's most recent trade in Adaptive Biotechnologies Corp was a trade of 2,145 Stock Option (right to buy) done . Disclosure was reported to the exchange on Feb. 4, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Adaptive biotech Corp | Kyle Piskel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Feb 2026 | 2,145 | 2,146 | - | - | Stock Option (right to buy) | |
| Adaptive biotech Corp | Kyle Piskel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 18.46 per share. | 04 Feb 2026 | 2,145 | 216,637 (0%) | 0% | 18.5 | 39,597 | Common Stock |
| Adaptive biotech Corp | Kyle Piskel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.14 per share. | 04 Feb 2026 | 2,145 | 218,782 (0%) | 0% | 12.1 | 26,040 | Common Stock |
| Adaptive biotech Corp | Kyle Piskel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.14 per share. | 12 Jan 2026 | 4,290 | 220,927 (0%) | 0% | 12.1 | 52,081 | Common Stock |
| Adaptive biotech Corp | Kyle Piskel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 18.00 per share. | 12 Jan 2026 | 4,290 | 216,637 (0%) | 0% | 18 | 77,220 | Common Stock |
| Adaptive biotech Corp | Kyle Piskel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jan 2026 | 4,290 | 4,291 | - | - | Stock Option (right to buy) | |
| Adaptive biotech Corp | Kyle Piskel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 19.50 per share. | 28 Nov 2025 | 162,820 | 216,637 (0%) | 0% | 19.5 | 3,174,990 | Common Stock |
| Adaptive biotech Corp | Kyle Piskel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Nov 2025 | 94,384 | 8,581 | - | - | Stock Option (right to buy) | |
| Adaptive biotech Corp | Kyle Piskel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.14 per share. | 28 Nov 2025 | 94,384 | 379,457 (0%) | 0% | 12.1 | 1,145,822 | Common Stock |
| Adaptive biotech Corp | Kyle Piskel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.55 per share. | 28 Nov 2025 | 11,980 | 281,323 (0%) | 0% | 6.6 | 78,469 | Common Stock |
| Adaptive biotech Corp | Kyle Piskel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Nov 2025 | 11,980 | 0 | - | - | Stock Option (right to buy) | |
| Adaptive biotech Corp | Kyle Piskel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Nov 2025 | 3,750 | 0 | - | - | Stock Option (right to buy) | |
| Adaptive biotech Corp | Kyle Piskel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.80 per share. | 28 Nov 2025 | 3,750 | 285,073 (0%) | 0% | 7.8 | 29,250 | Common Stock |
| Adaptive biotech Corp | Kyle Piskel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 14.05 per share. | 17 Nov 2025 | 238 | 269,343 (0%) | 0% | 14.1 | 3,344 | Common Stock |
| Adaptive biotech Corp | Kyle Piskel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 8.89 per share. | 16 May 2025 | 1,929 | 269,581 (0%) | 0% | 8.9 | 17,149 | Common Stock |
| Adaptive biotech Corp | Kyle Piskel | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2025 | 7,815 | 279,325 (0%) | 0% | 0 | Common Stock | |
| Adaptive biotech Corp | Kyle Piskel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 8.89 per share. | 15 May 2025 | 1,929 | 277,396 (0%) | 0% | 8.9 | 17,149 | Common Stock |
| Adaptive biotech Corp | Kyle Piskel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.32 per share. | 14 Mar 2025 | 2,500 | 271,510 (0%) | 0% | 6.3 | 15,800 | Common Stock |
| Adaptive biotech Corp | Kyle Piskel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2025 | 2,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Adaptive biotech Corp | Kyle Piskel | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 125,000 | 279,330 (0%) | 0% | 0 | Common Stock | |
| Adaptive biotech Corp | Kyle Piskel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 6.99 per share. | 04 Mar 2025 | 6,964 | 269,010 (0%) | 0% | 7.0 | 48,678 | Common Stock |
| Adaptive biotech Corp | Kyle Piskel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 6.97 per share. | 04 Mar 2025 | 3,103 | 276,227 (0%) | 0% | 7.0 | 21,628 | Common Stock |
| Adaptive biotech Corp | Kyle Piskel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 6.98 per share. | 04 Mar 2025 | 253 | 275,974 (0%) | 0% | 7.0 | 1,766 | Common Stock |
| Adaptive biotech Corp | Kyle Piskel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 4.98 per share. | 18 Nov 2024 | 248 | 154,330 (0%) | 0% | 5.0 | 1,235 | Common Stock |
| Adaptive biotech Corp | Kyle Piskel | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2024 | 31,260 | 154,578 (0%) | 0% | 0 | Common Stock | |
| Adaptive biotech Corp | Kyle Piskel | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2024 | 43,740 | 131,045 (0%) | 0% | 0 | Common Stock | |
| Adaptive biotech Corp | Kyle Piskel | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 3.43 per share. | 04 Mar 2024 | 7,727 | 123,318 (0%) | 0% | 3.4 | 26,504 | Common Stock |
| Adaptive biotech Corp | Kyle Piskel | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 43,735 | 91,093 (0%) | 0% | 0 | Common Stock | |
| Adaptive biotech Corp | Kyle Piskel | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 8.57 per share. | 06 Mar 2023 | 3,300 | 87,793 (0%) | 0% | 8.6 | 28,281 | Common Stock |
| Adaptive biotech Corp | Kyle Piskel | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 8.58 per share. | 06 Mar 2023 | 229 | 87,564 (0%) | 0% | 8.6 | 1,965 | Common Stock |
| Adaptive biotech Corp | Kyle Piskel | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 8.87 per share. | 16 Nov 2022 | 307 | 47,358 (0%) | 0% | 8.9 | 2,723 | Common Stock |
| Adaptive biotech Corp | Kyle Piskel | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2022 | 102,965 | 102,965 | - | - | Stock Option (Right to Buy) | |
| Adaptive biotech Corp | Kyle Piskel | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2022 | 41,186 | 47,885 (0%) | 0% | 0 | Common Stock | |
| Adaptive biotech Corp | Kyle Piskel | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 12.01 per share. | 04 Mar 2022 | 220 | 47,665 (0%) | 0% | 12.0 | 2,642 | Common Stock |
| Adaptive biotech Corp | Kyle Piskel | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Nov 2021 | 9,592 | 9,592 | - | - | Stock Option (Right to Buy) | |
| Adaptive biotech Corp | Kyle Piskel | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Nov 2021 | 3,837 | 6,699 (0%) | 0% | 0 | Common Stock |